FDA removes box warning from six hormone replacement therapies, impacting millions of menopausal women in the US.
Author: PharmaSignal News Desk
PharmaSignal Take This week’s events signal a continued focus on strategic M&A and licensing deals, particularly in genetic medicine and RNAi therapeutics. Lilly’s acquisitions and alliance with Innovent Biologics stress-test the assumption of platform scalability and integration readiness. Meanwhile, regulatory decisions are impacting market access and launch timing for a number of assets. The PharmaSignal Weekly Brief – Global Pharma Roundup captures these themes, providing insights into the strategic decisions and execution risks faced by global pharma leaders. M&A and Strategic Deals Lilly’s acquisition of Orna for $2.4B and partnership with Innovent Biologics for $9B underscore the company’s push into…
Madrigal RNAi drug deal involves a $4.4 billion agreement with a China-based biotech for six preclinical medicines.
Moderna mRNA flu vaccine faces a setback as the FDA refuses to review its application, citing inconsistencies with prior communications.
Regenxbio FDA rejection impacts its gene therapy for Hunter Syndrome, marking a significant regulatory setback.
Lilly acquires Orna for $2.4 billion, enhancing its genetic medicine portfolio with in vivo CAR-T technology.
Lilly Innovent Biologics alliance could reach $9 billion, focusing on drug development in China.
PharmaSignal Take This week’s events highlight the increased scrutiny on pricing practices and the continued push for innovation in the pharma industry. The FDA’s regulatory actions and the strategic deals being made underscore the importance of execution readiness and platform scalability in this rapidly evolving landscape. In this week’s PharmaSignal Weekly Brief – Global Pharma Roundup, we see a strong focus on regulatory actions, strategic deals, and pipeline developments. M&A and Strategic Deals AstraZeneca’s $15B investment in China’s drug development signals a strategic shift towards high-growth markets and underlines the importance of geographic optionality. Read more → Halozyme’s $400M acquisition…
Bayer Asundexian Stroke Prevention shows a 26% risk reduction in Phase 3 trial, boosting its commercial outlook.
Express Scripts settlement with FTC includes changes to insulin pricing practices and reshoring of rebate aggregator.